Cosentyx, Secukinumab (AIN457) approved for psoriasis
Posted: Tue Mar 03, 2015 11:41 am
Cosentyx, Secukinumab (AIN457) approved for psoriasis
Edit
Delete post
Report this post
Information
Quote
Postby Mike Bartolatz » Sun Feb 08, 2015 4:57 pm
this is a VERY big deal as IL17 blocking drug AIN457 was first tried in uveitis. this is the same drug! too few individuals for study approval by FDA because of Uveitis being a very rare condition and trials were not adequate to show possible contraindications.
this drug will be available on the orphan drug list for many conditions now and hopefully research will allow off label use in uveitis when the patient is shown to have the IL17A gene.
mike
________________________________________________________________________________________________________________
The US Food and Drug Administration (FDA) has approved the interleukin 17A inhibitor secukinumab (Cosentyx) for adults with moderate to severe plaque psoriasis.
Cosentyx is administered as a subcutaneous injection and may be used in combination with phototherapy.
In reports at the American College of Rheumatology meeting last November, secukinumab showed promising results against psoriatic arthritis (PsA) in Phase 3 trials. Observers have antipated that approval for psoriasis would predate any approval for Ps
.....- See more at: http://www.rheumatologynetwork.com/psor ... CTmFx.dpuf
Mike Bartolatz
Moderator
Edit
Delete post
Report this post
Information
Quote
Postby Mike Bartolatz » Sun Feb 08, 2015 4:57 pm
this is a VERY big deal as IL17 blocking drug AIN457 was first tried in uveitis. this is the same drug! too few individuals for study approval by FDA because of Uveitis being a very rare condition and trials were not adequate to show possible contraindications.
this drug will be available on the orphan drug list for many conditions now and hopefully research will allow off label use in uveitis when the patient is shown to have the IL17A gene.
mike
________________________________________________________________________________________________________________
The US Food and Drug Administration (FDA) has approved the interleukin 17A inhibitor secukinumab (Cosentyx) for adults with moderate to severe plaque psoriasis.
Cosentyx is administered as a subcutaneous injection and may be used in combination with phototherapy.
In reports at the American College of Rheumatology meeting last November, secukinumab showed promising results against psoriatic arthritis (PsA) in Phase 3 trials. Observers have antipated that approval for psoriasis would predate any approval for Ps
.....- See more at: http://www.rheumatologynetwork.com/psor ... CTmFx.dpuf
Mike Bartolatz
Moderator